Legal Opinion
Cipla USA, Inc. v. Ipsen Biopharmaceuticals, Inc.
District Court, D. Delaware
Decided June 15, 2023No. 1:22-cv-00552Unknown
1Opinion
IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE CIPLA USA, INC., Plaintiff, v. C.A. No. 22-552-GBW IPSEN BIOPHARMACEUTICALS, INC., Defendant. MEMORANDUM ORDER This action stems from a dispute regarding alleged violations of the Lanham Act, 15 U.S.C. § 1125(a), as well as other related state-law claims. See D.I. 1. On June 3, 2022, Defendant Ipsen Biopharmaceuticals (“Ipsen”) filed a Motion, under Federal Rules of Civil Procedure 12(b)(1) and 12(b)(6), to dismiss Plaintiff Cipla USA, Inc.’s (“Cipla”) Complaint. D.I. 16. The parties briefed the issues. See, e.g., DI. 17; D.I.…
2Cases cited13 opinions
- Ashcroft v. IqbalSupreme Court of the United States · 2009
- Bell Atlantic Corp. v. TwomblySupreme Court of the United States · 2007
- In Re Burlington Coat Factory Securities Litigation. P. Gregory Buchanan, Jacob Turner and Ronald AbramoffCourt of Appeals for the Third Circuit · 1997
- Henderson v. CarlsonCourt of Appeals for the Third Circuit · 1987
- Brown v. AstrueCourt of Appeals for the Third Circuit · 2011
8 more not listed; retrieve them via the Exa API.